FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MAYLEBEN TIMOTHY M						2. Issuer Name and Ticker or Trading Symbol <u>Esperion Therapeutics</u> , <u>Inc.</u> [ESPR]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
						1			,		-	-		X	Directo	r		10% Ow	ner	
(Last)	(F	irst)	(Middle)		3. [Date of Earliest Transaction (Month/Day/Year)									Officer below)	(give title		Other (s below)	pecify	
C/O ESPERION THERAPEUTICS, INC.						01/04/2016									President & CEO					
3891 RANCHERO DRIVE, SUITE 150																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street) ANN ARBOR MI 48108														Line) X Form filed by One Reporting Person						
ANTARDOR WII 40100														_	Form filed by More than One Reporting					
(City) (State) (Zip)														Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (In	Transaction Dispose Code (Instr. 5)		ties Acquired (A) o d Of (D) (Instr. 3, 4 a			5. Amour Securitie Beneficia Owned F	es For ally (D) collowing (I) (: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	,	Amount	(A) o (D)	r Prid	ce	Transact (Instr. 3 a	ion(s)			msu. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
									, options											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (l 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration I (Month/Day	Date		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		Derivativ Security		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C s F llly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amou or Numb of Share	er						
Stock Option (right to buy)	\$21.65	01/04/2016			A		30,000		(1)	01	/04/2026	Common Stock	30,0	00	\$0.00	21.65	5	D		

Explanation of Responses:

1. The options vest over a four (4) year period in equal quarterly installments, the first of which will be on April 4, 2016.

/s/ Richard B. Bartram, by power of attorney

01/05/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.